This review highlights the increased risk of cardiovascular disease and the dismal prognosis after acute coronary events when diabetes is present. Although there have been improvements in this area, diabetes still confers an increased risk. In order to achieve successful outcomes in individuals with diabetes, extensive treatment of risk factors and the use of all available evidence-based therapies are needed. In this context, glucose-lowering therapies and antithrombotic and revascularisation strategies are detailed in this review. Emerging data indicate that novel glucose-lowering drugs may impact cardiovascular outcome with mechanisms that are beyond glucose control. In addition, this review addresses hidden diabetes and impaired glucose tolerance in patients with acute and stable coronary artery disease and how they influence future cardiovascular risk.
International Diabetes Federation. IDF Diabetes Atlas, 7th edition. Available at: www.diabetesatlas.org (2016).
2.
LindMGarcia-RodriguezLABoothGL. Mortality trends in patients with and without diabetes in Ontario, Canada and the UK from 1996 to 2009: A population-based study. Diabetologia2013; 56: 2601–2608.
3.
NorhammarALindbäckJRydénL. Register of Information and Knowledge about Swedish Heart Intensive Care Admission (RIKS-HIA). Improved but still high short- and long-term mortality rates after myocardial infarction in patients with diabetes mellitus: A time-trend report from the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admission. Heart2007; 93: 1577–1583.
4.
DotevallAHasdaiDWallentinL. Diabetes mellitus: Clinical presentation and outcome in men and women with acute coronary syndromes. Data from the Euro Heart Survey ACS. Diabet Med2005; 22: 1542–1550.
5.
ArnoldSVLipskaKJLiY. Prevalence of glucose abnormalities among patients presenting with an acute myocardial infarction. Am Heart J2014; 168(4): 466–470.
NorhammarATenerzANilssonG. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: A prospective study. Lancet2002; 359(9324): 2140–2144.
8.
WallanderMMalmbergKNorhammarA. Oral glucose tolerance test: A reliable tool for early detection of glucose abnormalities in patients with acute myocardial infarction in clinical practice: A report on repeated oral glucose tolerance tests from the GAMI study. Diabetes Care2008; 31(1): 36–38.
9.
BartnikMRydénLFerrariR. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J2004; 25(21): 1880–1890.
10.
GybergVDe BacquerDKotsevaK. Screening for dysglycaemia in patients with coronary artery disease as reflected by fasting glucose, oral glucose tolerance test, and HbA1c: A report from EUROASPIRE IV – A survey from the European Society of Cardiology. Eur Heart J2015; 36(19): 1171–1177.
11.
RydénLGrantPJAnkerSD. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J2013; 34(39): 3035–3087.
12.
KannelWBMcGeeDL. Diabetes and cardiovascular disease. The Framingham Study. JAMA1979; 241: 2035–2039.
13.
YusufSHawkenSOunpuuS. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case–control study. Lancet2004; 364(9438): 937–952.
14.
ShahADLangenbergCRapsomanikiE. Type 2 diabetes and incidence of cardiovascular diseases: A cohort study in 1.9 million people. Lancet Diabetes Endocrinol2015; 3: 105–113.
15.
NorhammarABodegårdJNyströmT. Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: A nationwide study in Sweden, 2006–2013. Diabetologia2016; 59: 1692–1701.
16.
AliMKBullardKMSaaddineJB. Achievement of goals in U.S. diabetes care, 1999–2010. N Engl J Med2013; 368: 1613–1624.
17.
US Centers for Disease Control and Prevention (CDC), National Center for Health Statistics, Division of Health Care Statistics. Crude and age-adjusted hospital discharge rates for major cardiovascular disease as first-listed diagnosis per 1,000 diabetic population, United States, 1988–2006. Available at: http://www.cdc.gov/diabetes/statistics/cvdhosp/cvd/fig3.htm (2014, accessed 27 August 2015).
18.
GaedePLund-AndersenHParvingH-H. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med2008; 358: 580–591.
19.
EUROASPIRE I and II Group; European Action on Secondary Prevention by Intervention to Reduce Events. Clinical reality of coronary prevention guidelines: A comparison of EUROASPIRE I and II in nine countries. Lancet2001; 357(9261): 995–1001.
20.
JohanssonIDahlströmUEdnerM. Prognostic implications of diabetes in ischemic and non-ischemic heart failure in the Swedish Heart Failure Registry. J Am Coll Cardiol2016; 68: 1404–1416.
21.
Piepoli MF, Hoes AW, Agewell S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37(29): 2315–2381.
22.
American Diabetes Association. Standards of medical care in diabetes – 2017. Diabetes Care2017; 40: S1–S2.
23.
RitsingerVSalehNLagerqvistB. High event rate after a first percutaneous coronary intervention (PCI) in patients with diabetes. Results from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Circ Cardiovasc Interv2015; 8(6): e002328–e002328.
24.
RitsingerVTanoglidiEMalmbergK. Sustained prognostic implications of newly detected glucose abnormalities in patients with acute myocardial infarction: Long-term follow-up of the Glucose Tolerance in Patients with Acute Myocardial Infarction cohort. Diab Vasc Dis Res2015; 12: 23–32.
25.
GeorgeABhatiaRTBuchananGL. Impaired glucose tolerance or newly diagnosed diabetes mellitus diagnosed during admission adversely affects prognosis after myocardial infarction: an observational study. PLoS One2015; 10(11): e0142045–e0142045.
26.
MalmbergKNorhammarAWedelH. Glycometabolic state at admission: Important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction – Long-term results from the Diabetes and Insulin–Glucose Infusion in Acute Myocardial Infarction. Circulation1999; 99: 2626–2632.
27.
MalmbergKRydenLWedelH. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): Effects on mortality and morbidity. Eur Heart J2005; 26: 650–661.
28.
OpieLH. Metabolic management of acute myocardial infarction comes to the fore and extends beyond control of hyperglycemia. Circulation2008; 117: 2172–2177.
29.
KlonerRANestoRW. Glucose–insulin–potassium for acute myocardial infarction: Continuing controversy over cardioprotection. Circulation2008; 117: 2523–2533.
30.
SkylerJSBergenstalRBonowRO. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation2009; 119: 351–357.
31.
GotoAArahOAGotoM. Severe hypoglycaemia and cardiovascular disease: Systematic review and meta-analysis with bias analysis. BMJ2013; 347: 4533–4533.
32.
BeckmanJAPaneniFCosentinoF. Diabetes and vascular disease: Pathophysiology, clinical consequences, and medical therapy: Part II. Eur Heart J2013; 34: 2444–2452.
33.
BaigentCBlackwellLCollinsR. Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials. Lancet2009; 373: 1849–1860.
34.
RoffiMPatronoCColletJ-P. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J2016; 37(3): 267–315.
35.
SzummerKOldgrenJLindhagenL. Association between the use of fondaparinux vs low-molecular-weight heparin and clinical outcomes in patients with non-ST-segment elevation myocardial infarction. JAMA2015; 313: 707–716.
StenestrandUJamesSKLindbäckJ. Safety and efficacy of drug-eluting vs. bare metal stents in patients with diabetes mellitus: Long-term follow-up in the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J2010; 31(2): 177–186.
38.
SerruysPWMoriceMCKappeteinAP. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med2009; 360(10): 961–972.
39.
FarkouhMEDomanskiMSleeperLA. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med2012; 367: 2375–2384.
